AxoGen (NASDAQ:AXGN) Posts Earnings Results, Misses Expectations By $0.04 EPS

29 Apr 2026, 15:08 by Amy Steele · The Cerbat Gem

AxoGen (NASDAQ:AXGN – Get Free Report) posted its quarterly earnings results on Tuesday. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.04), FiscalAI reports. The company had revenue of $61.46 million during the quarter, compared to analysts’ expectations of $57.85 million. AxoGen had a negative return on equity of 13.44% and a negative net margin of 6.97%.

Here are the key takeaways from AxoGen’s conference call:

Delivered a strong Q1 with $61.5 million revenue (+26.6% YoY), $5.7 million Adjusted EBITDA, and a raised full‑year revenue target of at least 20% (~$270 million), supported by $103.6 million in cash and investments.
Avance received biologics license approval and is entering commercial channels in Q2 with no price change, enabling broader payer engagement and long‑term commercialization benefits despite expected near‑term gross margin pressure to the guided 74%–76% range.
Material reimbursement progress — Cigna issued broad coverage for extremity and post‑mastectomy use, Elevance/Anthem removed investigational status (initial gap‑length limits applied), and an Aetna decision could push coverage to the mid‑90s of commercial lives.
Commercial expansion is accelerating with a 146‑rep field organization, rep productivity ahead of plan, a meaningful increase in active surgeons, and broad double‑digit growth across extremities, OMF/head & neck, and breast (breast fastest growing).
GAAP net loss was $19.6 million (includes a one‑time $16.8 million debt extinguishment), but adjusted net income was positive ($4.1 million), adjusted EBITDA improved, and the company expects to be free‑cash‑flow positive for full‑year 2026 after raising $133.3 million in January.

AxoGen Stock Down 1.2%

AXGN traded down $0.50 during midday trading on Wednesday, hitting $41.50. 671,920 shares of the company’s stock traded hands, compared to its average volume of 1,048,300. The company has a market cap of $2.15 billion, a PE ratio of -122.10 and a beta of 0.98. The stock’s fifty day simple moving average is $33.36 and its 200-day simple moving average is $30.21. The company has a debt-to-equity ratio of 0.51, a current ratio of 5.11 and a quick ratio of 3.31. AxoGen has a one year low of $9.22 and a one year high of $45.83.

Wall Street Analyst Weigh In

AXGN has been the topic of several recent research reports. Citizens Jmp raised their price objective on shares of AxoGen from $42.00 to $50.00 and gave the company a “market outperform” rating in a research report on Wednesday. Wells Fargo & Company raised their price objective on shares of AxoGen from $40.00 to $48.00 and gave the company an “overweight” rating in a research report on Wednesday. Canaccord Genuity Group set a $50.00 price objective on shares of AxoGen in a research report on Wednesday. HC Wainwright raised their price objective on shares of AxoGen from $39.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Lake Street Capital raised their price objective on shares of AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, AxoGen presently has an average rating of “Moderate Buy” and an average price target of $46.50.

Check Out Our Latest Research Report on AxoGen

Insider Buying and Selling

In other AxoGen news, insider Erick Wayne Devinney sold 5,221 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $32.84, for a total transaction of $171,457.64. Following the transaction, the insider owned 262,781 shares in the company, valued at $8,629,728.04. This trade represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.78% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AxoGen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC grew its holdings in AxoGen by 1.2% during the second quarter. First Light Asset Management LLC now owns 4,529,243 shares of the medical equipment provider’s stock valued at $49,142,000 after purchasing an additional 55,028 shares during the last quarter. Morgan Stanley grew its holdings in AxoGen by 6.5% during the fourth quarter. Morgan Stanley now owns 2,586,870 shares of the medical equipment provider’s stock valued at $84,668,000 after purchasing an additional 157,029 shares during the last quarter. Balyasny Asset Management L.P. grew its holdings in AxoGen by 183.9% during the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock valued at $20,953,000 after purchasing an additional 1,250,968 shares during the last quarter. Wasatch Advisors LP grew its holdings in AxoGen by 14.3% during the third quarter. Wasatch Advisors LP now owns 1,639,351 shares of the medical equipment provider’s stock valued at $29,246,000 after purchasing an additional 205,569 shares during the last quarter. Finally, Soleus Capital Management L.P. grew its holdings in AxoGen by 0.9% during the second quarter. Soleus Capital Management L.P. now owns 1,459,395 shares of the medical equipment provider’s stock valued at $15,834,000 after purchasing an additional 13,278 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

More AxoGen News

Here are the key news stories impacting AxoGen this week:

Positive Sentiment: Two brokerages raised targets and upgraded the stock — Citizens JMP lifted its price target to $50 and assigned a “market outperform” rating (≈20% upside to current levels). Article Title
Positive Sentiment: Wells Fargo raised its target to $48 and moved to an “overweight” rating (≈15–16% upside), providing additional analyst-led upside momentum. Article Title
Neutral Sentiment: Q1 results were mixed: revenue of $61.46M beat consensus (~$57.8M), but EPS of $0.07 missed estimates (~$0.11–$0.12). The top‑line beat supports growth narrative; the EPS miss and negative margins/ROE keep profitability concerns in focus. Article Title
Neutral Sentiment: Management hosted an earnings presentation and call (transcript and slide deck available) — useful for detail on demand trends, margin drivers, and any FY2026 guidance specifics (guidance referenced but not fully spelled out in filings). Investors should review the call slides/transcript for forward-looking color. Article Title
Negative Sentiment: Zacks downgraded AXGN from “hold” to “strong sell,” which could pressure sentiment and trigger short-term selling by retail or model-driven funds. Article Title

AxoGen Company Profile

(Get Free Report)

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.